Synthetic Rigidin Analogues for Anticancer Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer agents derived from natural sources, such as rigidins, face challenges due to limited availability and inefficient synthesis, leading to underexplored biological properties and weak antiproliferative activities against cancer cell lines.
Innovation Solution
Development of novel four-component reaction methods to synthesize hypoxanthine-like rigidin analogues, which exhibit potent antiproliferative effects at low concentrations, overcoming the limitations of previous synthetic approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural rigidins are used as anticancer agents, then biological activity is achieved, but availability is limited and synthesis is inefficient
Solution Approach 1:
The patent modifies the chemical structure of natural rigidins by introducing hypoxanthine-like analogues with altered molecular parameters. This structural modification enables improved synthesis efficiency through the four-component reaction while maintaining or enhancing antiproliferative activity against cancer cell lines.
Solution Approach 2:
Instead of directly using natural rigidins which are difficult to obtain, the patent creates synthetic copies (analogues) that replicate the core biological activity. These copied structures can be produced more efficiently through chemical synthesis methods, specifically the four-component reaction described in the patent.
2Reliability
If natural rigidins are used, then anticancer effects are observed, but availability from natural sources is insufficient
Solution Approach 1:
The patent enables self-sufficient production of rigidin analogues through chemical synthesis, eliminating dependence on natural sources. The four-component reaction provides a self-contained synthetic pathway that can generate sufficient quantities of compounds without requiring extraction from natural materials.
Solution Approach 2:
By changing the molecular parameters to create analogues rather than using exact natural structures, the patent enables scalable synthesis. The modified structures maintain the essential pharmacophore features for anticancer activity while allowing for efficient production through chemical methods.
3Quantity of substance
If previous synthetic methods are used for rigidins, then some production is achieved, but synthesis efficiency remains poor
Solution Approach 1:
The patent combines four different components in a single reaction step to construct the rigidin analogue structure. This merging of multiple synthetic steps into one four-component reaction dramatically improves overall synthesis efficiency by reducing the number of isolation and purification steps required.
Solution Approach 2:
The four-component reaction is designed so that all necessary molecular components are prepared and positioned in advance to react simultaneously. This preliminary organization of reactants allows for efficient one-step construction of the complex rigidin analogue structure, maximizing synthesis productivity.
Data Source
AI summary
A compound having the Formula as follows:wherein R, R1 and R2 are selected from hydrogen, aryl, fused aryl, heteroaryl, saturated carbocylclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic, C1-10 alkyl, haloalkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, alkenylalkyl, alkynylalkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitroalkyl, cyanoalkyl, acetamidoalkyl, and acyloxyalkyl. A process for the preparation thereof is also provided.